Similarly, HER2-targeting aptamers have been used to modify exosomes for enhanced delivery to HER2-positive breast cancer cells, overcoming resistance to HER2 inhibitors such as trastuzumab (Tao et al., 2023). Here, ERBB2 is linked to breast cancer.